General Information of Drug (ID: DMYDGH4)

Drug Name
4-((1H-imidazol-1-yl)methyl)phenol Drug Info
Synonyms
4-(1h-imidazol-1-ylmethyl)phenol; 1-(4-Hydroxybenzyl)imidazole; 41833-17-4; 4-((1H-imidazol-1-yl)methyl)phenol; Phenol, 4-(1H-imidazol-1-ylmethyl)-; CHEMBL166845; ZEFROCQEWXHIEP-UHFFFAOYSA-N; 4-(imidazolylmethyl)phenol; 4-Hobi; n-p-hydroxybenzylimidazole; AC1L4X2E; AC1Q7A8C; 4-Imidazol-1-ylmethyl-phenol; 4-(1h-imidazolylmethyl)phenol; 4-(imidazol-1-ylmethyl)phenol; SCHEMBL6323414; 4-[(1-imidazolyl)methyl]phenol; CTK4I5281; DTXSID30194643; MolPort-006-827-429; 1-(4-Hydroxybenzyl)-1H-imidazole; ZINC13549136; SBB051635
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
193822
CAS Number
CAS 41833-17-4
TTD Drug ID
DMYDGH4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Abiraterone acetate DMANBZI Prostate cancer 2C82.0 Approved [2]
ABIRATERONE DM8V75C Prostate cancer 2C82.0 Approved [3]
TAK-700 DM2H8FZ Prostate cancer 2C82.0 Phase 3 [4]
Seviteronel DM9IMEZ Breast cancer 2C60-2C65 Phase 2 [5]
CFG920 DM2BXDU Prostate cancer 2C82.0 Phase 1/2 [6]
DST-2970 DM69ZBU Prostate cancer 2C82.0 Phase 1 [7]
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol DM6Z5EK Discovery agent N.A. Investigative [8]
4-Indan-(1Z)-ylidenemethyl-pyridine DM25DR7 Discovery agent N.A. Investigative [9]
4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMIEMWA Discovery agent N.A. Investigative [8]
4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMY08FE Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Inhibitor [1]

References

1 Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as pote... Bioorg Med Chem Lett. 2010 Sep 1;20(17):5345-8.
2 CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids.2015 Mar;95:80-7.
3 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
4 Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78.
7 Clinical pipeline report, company report or official report of DisperSol Technologies.
8 Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
9 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.